Group __B___

FOIA/PA NO: ___2016-0068_____

RECORDS BEING RELEASED IN PART

The following types of information are being withheld:

Ex. 1: ☐ Records properly classified pursuant to Executive Order 13526
Ex. 2: ☐ Records regarding personnel rules and/or human capital administration
Ex. 3: ☐ Information about the design, manufacture, or utilization of nuclear weapons
☐ Information about the protection or security of reactors and nuclear materials
☐ Contractor proposals not incorporated into a final contract with the NRC
☐ Other_____
Ex. 4: ☐ Proprietary information provided by a submitter to the NRC
☐ Other_____
Ex. 5: ☐ Draft documents or other pre-decisional deliberative documents (D.P. Privilege)
☐ Records prepared by counsel in anticipation of litigation (A.W.P. Privilege)
☐ Privileged communications between counsel and a client (A.C. Privilege)
☐ Other_____
Ex. 6: ☐ Agency employee PII, including SSN, contact information, birthdates, etc.
☐ Third party PII, including names, phone numbers, or other personal information
Ex. 7(A): ☐ Copies of ongoing investigation case files, exhibits, notes, ROI's, etc.
☐ Records that reference or are related to a separate ongoing investigation(s)
Ex. 7(C): ☐ Special Agent or other law enforcement PII
☐ PII of third parties referenced in records compiled for law enforcement purposes
Ex. 7(D): ☐ Witnesses' and Allegers' PII in law enforcement records
☐ Confidential Informant or law enforcement information provided by other entity
Ex. 7(E): ☐ Law Enforcement Technique/Procedure used for criminal investigations
☐ Technique or procedure used for security or prevention of criminal activity
Ex. 7(F): ■ Information that could aid a terrorist or compromise security

Other/Comments:_____
_____

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 11

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated February 22, 2000,
1. Evergreen Radiology Associates, P.A.	3. License number 29-02023-06 is amended in its entirety to read as follows:
2. 785 Totowa Road Totowa, New Jersey 07512	4. Expiration date August 31, 2001
	5. Docket No. 030-32352 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Phosphorus 32	A. As identified in 35.300	A. 200 millicuries
B. Strontium 89	B. As identified in 35.300	B. 200 millicuries
C. Iodine 131	C. As identified in 35.300	C. 200 millicuries
D. Strontium 90	D. As identified in 35.400	D. 115 millicuries
E. Iodine 125	E. As identified in 35.400	E. 1000 millicuries
F. Iridium 192	F. Sealed Source (b)(7)(F) (b)(7)(F) (b)(7)(F)	F. Not to exceed (b)(7)(F) curies per source and (b)(7)(F) curies total
G. Iridium 192	G. Sealed Source (b)(7)(F) (b)(7)(F) (b)(7)(F)	G. Not to exceed (b)(7)(F) curies per source and (b)(7)(F) curies total

9. Authorized use:

A. through C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.

D. Treatment of superficial eye conditions using an applicator distributed pursuant to 10 CFR 32.74.

E. Any brachytherapy procedure approved in 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.

F. One source to be used in an (b)(7)(F) High Dose Rate Remote Afterloading Brachytherapy Device for interstitial, intracavitary, or bronchial therapy. The activity of the installed

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-02023-06

Docket or Reference Number
030-32352

Amendment No. 11

(b)(7)(F) source shall not exceed curies. One source in its shipping container to be in possession of the licensee as necessary for replacement of the source in the irradiation device.

G. One source to be used in a (b)(7)(F) Remote Afterloading Brachytherapy Unit for interstitial, intracavitary, intraluminal and gynecological radiotherapy in humans. The activity of the installed source shall not exceed 10 curies. One source in its shipping container for source replacement.

CONDITIONS

10. A. Licensed material may be used only at the licensee's facilities at (b)(7)(F) Totowa, New Jersey, and at the Radiation Medicine Center at Cape May, (b)(7)(F) Cape May Court House, New Jersey.

B. Licensed material in items 6.E may be used at the Clifton Surgery Center, (b)(7)(F) Clifton, New Jersey; and at Wills Surgery Center of Cape May County, (b)(7)(F) (b)(7)(F) Cape May Court House, New Jersey.

11. The Radiation Safety Officer for this license is Sam I. Brown, M.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
Sam I. Brown, M.D.	Phosphorus 32 as identified in 10 CFR 35.300 Strontium 89 as identified in 10 CFR 35.300 Iodine 131 as identified in 10 CFR 35.300 Strontium 90 as identified in 10 CFR 35.400 Iodine 125 as identified in 10 CFR 35.400 Iridium 192 for uses in a High Dose Rate Remote Afterloading Brachytherapy Device
Arthur Harvey, M.D.	Phosphorus 32 as identified in 10 CFR 35.300 Strontium 89 as identified in 10 CFR 35.300 Iodine 131 as identified in 10 CFR 35.300 Strontium 90 as identified in 10 CFR 35.400 Iodine 125 as identified in 10 CFR 35.400 Iridium 192 for uses in a High Dose Rate Remote Afterloading Brachytherapy Device

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-02023-06

Docket or Reference Number
030-32352

Amendment No. 11

Authorized Users	Material and Use
Sung I. Lee, M.D.	Phosphorus 32 as identified in 10 CFR 35.300 Strontium 89 as identified in 10 CFR 35.300 Iodine 131 as identified in 10 CFR 35.300 Strontium 90 as identified in 10 CFR 35.400 Iodine 125 as identified in 10 CFR 35.400 Iridium 192 for uses in a High Dose Rate Remote Afterloading Brachytherapy Device
John Leung, M.D.	Phosphorus 32 as identified in 10 CFR 35.300 Strontium 89 as identified in 10 CFR 35.300 Iodine 131 as identified in 10 CFR 35.300 Strontium 90 as identified in 10 CFR 35.400 Iodine 125 as identified in 10 CFR 35.400 Iridium 192 for uses in a High Dose Rate Remote Afterloading Brachytherapy Device

13. The Medical Physicists for this license are Sreenivasa Murthy, M.S., Xuan Gen Chen, Ph.D., Michael P. Nunno, Robert Stanton, and Cheryl Trail.

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.

15. In lieu of 10 CFR 35.404(a), immediately after retracting the source from the patient into its shielded position in the remote afterloading device, radiation survey shall be made of the patient and the remote afterloading device with a portable radiation detection survey instrument to confirm that the source has been removed from the patient. Records of the survey shall be maintained in lieu of the record required in 10 CFR 35.404(b).

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-02023-06

Docket or Reference Number
030-32352

Amendment No. 11

16. In lieu of the source inventory described in 10 CFR 35.406, the licensee shall:

    A. Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each high dose remote brachytherapy procedure.

    B. Promptly make a survey of the area of use to confirm that no sources have been misplaced.

    C. Make a record of the survey including survey instrument used, dose rate, time, date and name of the individual making the survey.

    D. Retain the record of the survey in lieu of the record required in 10 CFR 35.406(d).

17. Prior to initiation of a treatment program, and subsequent to each source exchange for each high dose rate remote afterloading brachytherapy unit, a radiation survey shall be made of:

    A. The source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the surface of the main source safe shall not exceed 1 millirem per hour.

    B. All areas adjacent to the treatment room with the source in the exposed position. The survey shall clearly establish:

        (1) That radiation doses to occupationally exposed individuals do not exceed the limits specified in 10 CFR 20.1201(a), 20.1207 and 20.1208.

        (2) That radiation doses to individual members of the public do not exceed the limits specified in 10 CFR 20.1301(a).

18. The following shall be performed only by persons specifically authorized by the Commission or an Agreement State to perform such service:

    A. Installation, and replacement of the sealed sources contained in each high dose rate remote afterloading brachytherapy unit.

    B. Maintenance or repair operations on any high dose rate remote afterloading brachytherapy unit and associated equipment involving work on the source safe, the source driving unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-02023-06

Docket or Reference Number
030-32352

Amendment No. 11

19. A. Access to the treatment room housing each high dose rate remote afterloading brachytherapy unit shall be controlled by a door at each entrance.

    B. Each entrance to the treatment room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

    C. Electrical interlocks on each entrance door to the treatment room shall be tested for proper operation at least once each day of use.

    D. In the event of malfunction of the door interlock, the unit shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

20. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."